Search Results - "Pitcher, Bethany"

Patient-Derived Xenograft Establishment from Human Malignant Pleural Mesothelioma by Wu, Licun, Allo, Ghassan, John, Thomas, Li, Ming, Tagawa, Tetsuzo, Opitz, Isabelle, Anraku, Masaki, Yun, Zhihong, Pintilie, Melania, Pitcher, Bethany, Liu, Geoffrey, Feld, Ron, Johnston, Michael R, de Perrot, Marc, Tsao, Ming-Sound

“…Malignant pleural mesothelioma (MPM) is a rare but aggressive disease with few therapeutic options. The tumor-stromal interface is important in MPM, but this…”
Get full text

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC by Drilon, Alexander, Chiu, Chao-Hua, Fan, Yun, Cho, Byoung Chul, Lu, Shun, Ahn, Myung-Ju, Krebs, Matthew G., Liu, Stephen V., John, Thomas, Otterson, Gregory A., Tan, Daniel S.W., Patil, Tejas, Dziadziuszko, Rafal, Massarelli, Erminia, Seto, Takashi, Doebele, Robert C., Pitcher, Bethany, Kurtsikidze, Nino, Heinzmann, Sebastian, Siena, Salvatore

“…Entrectinib is an approved tyrosine kinase inhibitor (TKI) for ROS1 fusion–positive NSCLC. An updated integrated analysis of entrectinib from the ALKA-372-001,…”
Get full text

MATE2 Expression Is Associated with Cancer Cell Response to Metformin by Chowdhury, Sanjana, Yung, Eric, Pintilie, Melania, Muaddi, Hala, Chaib, Selim, Yeung, ManTek, Fusciello, Manlio, Sykes, Jenna, Pitcher, Bethany, Hagenkort, Anna, McKee, Trevor, Vellanki, Ravi, Chen, Eric, Bristow, Robert G, Wouters, Bradly G, Koritzinsky, Marianne

“…There is great interest in repurposing the commonly prescribed anti-diabetic drug metformin for cancer therapy. Intracellular uptake and retention of metformin…”
Get full text

Assessment of a prognostic model, PSA metrics and toxicities in metastatic castrate resistant prostate cancer using data from Project Data Sphere (PDS) by Pitcher, Bethany, Khoja, Leila, Hamilton, Robert J, Abdallah, Kald, Pintilie, Melania, Joshua, Anthony M

“…Prognostic models in metastatic castrate resistant prostate cancer (mCRPC) may have clinical utility. Using data from PDS, we aimed to 1) validate a…”
Get full text

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts by Lohse, Ines, Kumareswaran, Ramya, Cao, Pinjiang, Pitcher, Bethany, Gallinger, Steven, Bristow, Robert G, Hedley, David W

“…The BRCA2 gene product plays an important role in DNA double strand break repair. Therefore, we asked whether radiation sensitivity of pancreatic cancers…”
Get full text

Improved detection of clinically relevant wound bacteria using autofluorescence image‐guided sampling in diabetic foot ulcers by Ottolino‐Perry, Kathryn, Chamma, Emilie, Blackmore, Kristina M, Lindvere‐Teene, Liis, Starr, Danielle, Tapang, Kim, Rosen, Cheryl F, Pitcher, Bethany, Panzarella, Tony, Linden, Ron, DaCosta, Ralph S

“…Clinical wound assessment involves microbiological swabbing of wounds to identify and quantify bacterial species, and to determine microbial susceptibility to…”
Get full text

BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE-BASKET Study by Kaley, Thomas, Touat, Mehdi, Subbiah, Vivek, Hollebecque, Antoine, Rodon, Jordi, Lockhart, A Craig, Keedy, Vicki, Bielle, Franck, Hofheinz, Ralf-Dieter, Joly, Florence, Blay, Jean-Yves, Chau, Ian, Puzanov, Igor, Raje, Noopur S, Wolf, Jurgen, DeAngelis, Lisa M, Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, Baselga, Jose, Hyman, David M

“…PURPOSEBRAFV600 mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less…”
Get full text

Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer by Goody, Rebecca B., MBChB, MacKay, Helen, MBChB, MD, Pitcher, Bethany, MSc, Oza, Amit, MD, Siu, Lillian L., MD, Kim, John, MD, Wong, Rebecca K.S., MBChB, MSc, Chen, Eric, MD, Swallow, Carol, MD, Knox, Jennifer, MD, Kassam, Zahra, MBBS, MSc, Cummings, Bernard, MBChB, Feld, Ron, MD, Hedley, David, MD, Liu, Geoffrey, MD, Krzyzanowska, Monika K., MD, Dinniwell, Robert, MD, MSc, Brade, Anthony M., MD, CM, PhD, Dawson, Laura A., MD, Pintilie, Melania, MSc, Ringash, Jolie, MD, MSc

“…Purpose Locoregional recurrence is common after surgery for gastric cancer. Adjuvant therapy improves outcomes but with toxicity. This phase 1/2 study…”
Get full text

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors by Demetri, George D, De Braud, Filippo, Drilon, Alexander, Siena, Salvatore, Patel, Manish R, Cho, Byoung Chul, Liu, Stephen V, Ahn, Myung-Ju, Chiu, Chao-Hua, Lin, Jessica J, Goto, Koichi, Lee, Jeeyun, Bazhenova, Lyudmila, John, Thomas, Fakih, Marwan, Chawla, Sant P, Dziadziuszko, Rafal, Seto, Takashi, Heinzmann, Sebastian, Pitcher, Bethany, Chen, David, Wilson, Timothy R, Rolfo, Christian

“…Entrectinib potently inhibits tropomyosin receptor kinases (TRKAs)/B/C and ROS1, and previously induced deep [objective response rate (ORR) 57.4%] and durable…”
Get full text

Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC) by Labbé, Catherine, Cabanero, Michael, Korpanty, Grzegorz J., Tomasini, Pascale, Doherty, Mark K., Mascaux, Céline, Jao, Kevin, Pitcher, Bethany, Wang, Rick, Pintilie, Melania, Leighl, Natasha B., Feld, Ronald, Liu, Geoffrey, Bradbury, Penelope Ann, Kamel-Reid, Suzanne, Tsao, Ming-Sound, Shepherd, Frances A.

“…•In EGFR-mutated NSCLC, TP53 co-mutation is not a strong prognostic marker.•TP53 missense mutations might be predictive of lower ORR and shorter PFS on…”
Get full text

Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study by Diamond, Eli L, Subbiah, Vivek, Lockhart, A Craig, Blay, Jean-Yves, Puzanov, Igor, Chau, Ian, Raje, Noopur S, Wolf, Jurgen, Erinjeri, Joseph P, Torrisi, Jean, Lacouture, Mario, Elez, Elena, Martínez-Valle, Ferran, Durham, Benjamin, Arcila, Maria E, Ulaner, Gary, Abdel-Wahab, Omar, Pitcher, Bethany, Makrutzki, Martina, Riehl, Todd, Baselga, José, Hyman, David M

“…The histiocytic neoplasms Erdheim-Chester disease (ECD) and Langerhans cell histiocytosis (LCH) are highly enriched for BRAF V600 mutations and have been…”
Get more information

Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive ( NTRK -fp) solid tumors by Krzakowski, Maciej Jerzy, Lu, Shun, Cousin, Sophie, Smit, Egbert F., Springfeld, Christoph, Goto, Koichi, Garrido, Pilar, Chung, Christine H., Lin, Jessica Jiyeong, Bray, Victoria J., Pitcher, Bethany, Zeuner, Harald, Patel, Siddhartha, Bordogna, Walter, Gelderblom, Hans

“…3099 Background: NTRK gene fusions, coding for chimeric TRK proteins, are oncogenic drivers in many solid tumors. In an integrated analysis of three phase 1/2…”
Get full text

Mitochondrial Aconitase ACO2 Links Iron Homeostasis with Tumorigenicity in Non-Small Cell Lung Cancer by Mirhadi, Shideh, Zhang, Wen, Pham, Nhu-An, Karimzadeh, Fereshteh, Pintilie, Melania, Tong, Jiefei, Taylor, Paul, Krieger, Jonathan, Pitcher, Bethany, Sykes, Jenna, Wybenga-Groot, Leanne, Fladd, Christopher, Xu, Jing, Wang, Tao, Cabanero, Michael, Li, Ming, Weiss, Jessica, Sakashita, Shingo, Zaslaver, Olga, Yu, Man, Caudy, Amy A, St-Pierre, Julie, Hawkins, Cynthia, Kislinger, Thomas, Liu, Geoffrey, Shepherd, Frances A, Tsao, Ming-Sound, Moran, Michael F

“…The ability of a patient tumor to engraft an immunodeficient mouse is the strongest known independent indicator of poor prognosis in early-stage non-small cell…”
Get full text

Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors by Demetri, George D, De Braud, Filippo, Drilon, Alexander, Siena, Salvatore, Patel, Manish R, Cho, Byoung Chul, Liu, Stephen V, Ahn, Myung-Ju, Chiu, Chao-Hua, Lin, Jessica J, Goto, Koichi, Lee, Jeeyun, Bazhenova, Lyudmila, John, Thomas, Fakih, Marwan, Chawla, Sant P, Dziadziuszko, Rafal, Seto, Takashi, Heinzmann, Sebastian, Pitcher, Bethany, Chen, David, Wilson, Timothy R, Rolfo, Christian

Get full text

Efficacy and safety of entrectinib in patients (pts) with NTRK -fusion positive ( NTRK -fp) solid tumors: An updated integrated analysis by Rolfo, Christian Diego, De Braud, Filippo G., Doebele, Robert Charles, Drilon, Alexander E., Siena, Salvatore, Patel, Manish, Cho, Byoung Chul, Liu, Stephen V., Ahn, Myung-Ju, Chiu, Chao-Hua, Farago, Anna F., Goto, Koichi, Lee, Jeeyun, Bazhenova, Lyudmila, John, Tom, Fakih, Marwan, Simmons, Brian P., Pitcher, Bethany, Huang, Xinhui, Demetri, George D.

“…Abstract only 3605 Background: NTRK gene fusions lead to transcription of chimeric TRK proteins with overexpressed kinase function. Entrectinib is a potent…”
Get full text

A proposal for cellularity assessment for EGFR mutational analysis with a correlation with DNA yield and evaluation of the number of sections obtained from cell blocks for immunohistochemistry in non-small cell lung carcinoma by da Cunha Santos, Gilda, Wyeth, Tyler, Reid, Allie, Saieg, Mauro Ajaj, Pitcher, Bethany, Pintilie, Melania, Kamel-Reid, Suzanne, Tsao, Ming Sound

“…Different approaches have been described for reporting specimen adequacy for epidermal growth factor receptor (EGFR) mutation analysis. We aimed: (1) to…”
Get more information

A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC) by Bendell, Johanna C., Bang, Yung-Jue, Chee, Cheng Ean, Ryan, David P., McRee, Autumn Jackson, Chow, Laura Q., Desai, Jayesh, Wongchenko, Matthew, Yan, Yibing, Pitcher, Bethany, Foster, Paul, Cha, Edward, Grossman, William, Kim, Tae Won

“…Abstract only 560 Background: The majority of pts with mCRC have microsatellite stable (MSS) tumors with minimal response to PD-L1/PD-1 blockade. MEK…”
Get full text

BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study by Kaley, Thomas, Touat, Mehdi, Subbiah, Vivek, Hollebecque, Antoine, Rodon, Jordi, Lockhart, A Craig, Keedy, Vicki, Bielle, Franck, Hofheinz, Ralf-Dieter, Joly, Florence, Blay, Jean-Yves, Chau, Ian, Puzanov, Igor, Raje, Noopur S, Wolf, Jurgen, DeAngelis, Lisa M, Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, Baselga, Jose, Hyman, David M

“…mutations are frequently found in several glioma subtypes, including pleomorphic xanthoastrocytoma (PXA) and ganglioglioma and much less commonly in…”
Get full text

Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAF V600 mutation by Subbiah, Vivek, Gervais, Radj, Riely, Gregory J., Hollebecque, Antoine, Blay, Jean-Yves, Felip, Enriqueta, Schuler, Martin H., Goncalves, Anthony, Italiano, Antoine, Keedy, Vicki Leigh, Chau, Ian, Puzanov, Igor, Raje, Noopur, Makrutzki, Martina, Riehl, Todd, Pitcher, Bethany, Hyman, David Michael, Baselga, Jose

“…Abstract only 9074 Background: BRAF V600 mutations occur in 1–2% of pts with NSCLC. We previously reported the efficacy of vemurafenib, a selective BRAF V600…”
Get full text

Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity by Miller, Wilson H., Kim, Tae Min, Lee, Carrie B., Flaherty, Keith T., Reddy, Sunil, Jamal, Rahima, Chow, Laura Q., Rooney, Isabelle Anne, Pitcher, Bethany, Cha, Edward, Infante, Jeffrey R.

“…Abstract only 3057 Background: A, an anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, inhibits PD-L1/programmed death-1 (PD-1) and PD-L1/B7.1…”
Get full text